论文部分内容阅读
目的评价生长抑素对重症急性胰腺炎的临床治疗效果。方法计算机检索Cochrane图书馆临床对照试验库(2010年第3期),PubMed数据库(1966—2010年)、中国期刊文献数据库(CNKI,1994—2010年)、相关会议论文集及药厂资料,纳入随机对照试验,采用Rev Man 5.0进行系统评价。结果研究共纳入合格国内外随机对照试验9篇,包括重症急性胰腺炎患者785例;结果显示,干预组与对照组相比,住院时间、并发症、病死率差异均有统计学意义;住院时间加权均数差-14.89[95%可信区间(CI)-16.15,-13.64],并发症OR=0.58(95%CI 0.41~0.83),病死率OR=0.34(95%CI 0.23~0.52)。结论在重症急性胰腺炎治疗中应用生长抑素,可减少患者并发症、住院时间、病死率,有很好临床价值。
Objective To evaluate the clinical effect of somatostatin on severe acute pancreatitis. Methods The Cochrane Central Register of Controlled Trials (No. 3 of 2010), PubMed (1966-2010), Chinese Journal Literature Database (CNKI, 1994-2010) were searched by computer. A randomized controlled trial, a systematic review using Rev Man 5.0. Results A total of 9 randomized controlled trials were included in the study, including 785 cases of severe acute pancreatitis. The results showed that there were significant differences in hospitalization time, complications and mortality between the intervention group and the control group. The length of hospital stay Weighted mean difference -14.89 [95% confidence interval (CI) -16.15, -13.64], complication OR = 0.58 (95% CI 0.41-0.83), mortality was 0.34 (95% CI 0.23-0.52). Conclusions The application of somatostatin in the treatment of severe acute pancreatitis can reduce the complication, length of stay and mortality of patients with good clinical value.